This Is What Whales Are Betting On Pfizer

High-rolling investors have positioned themselves bullish on Pfizer PFE, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in PFE often signals that someone has privileged information.

Today, Benzinga's options scanner spotted 9 options trades for Pfizer. This is not a typical pattern.

The sentiment among these major traders is split, with 55% bullish and 44% bearish. Among all the options we identified, there was one put, amounting to $28,350, and 8 calls, totaling $607,915.

Projected Price Targets

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $27.5 for Pfizer over the last 3 months.

Volume & Open Interest Trends

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pfizer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pfizer's substantial trades, within a strike price spectrum from $15.0 to $27.5 over the preceding 30 days.

Pfizer Option Activity Analysis: Last 30 Days

Biggest Options Spotted:

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

After a thorough review of the options trading surrounding Pfizer, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Present Market Standing of Pfizer

• Currently trading with a volume of 15,591,857, the PFE's price is up by 0.74%, now at $26.55.
• RSI readings suggest the stock is currently may be approaching overbought.
• Anticipated earnings release is in 43 days.

Expert Opinions on Pfizer

3 market experts have recently issued ratings for this stock, with a consensus target price of $31.333333333333332.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Reflecting concerns, an analyst from B of A Securities lowers its rating to Neutral with a new price target of $29. * An analyst from Guggenheim has decided to maintain their Buy rating on Pfizer, which currently sits at a price target of $33. * Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Pfizer with a target price of $32.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with Benzinga Pro for real-time alerts.